Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of Formula (I):



(I)

wherein:

R^1 and R^2 are independently selected from the group consisting of hydrogen, halo, alkyl, alkylthio, nitro, trihalomethyl, hydroxy, hydroxyalkyl, alkoxy, cyano, aryl, heteroaryl, -$C(O)R^7$ (where R^7 is selected from the group consisting of alkyl, amino, hydroxy, alkoxy, aryl, heteroaryl, aryloxy, heteroaryloxy, heterocycle, and aminoalkylamino), -NR^8R^9, -$NR^8C(O)R^9$, -SO_2R^8, and –$S(O)_2NR^8R^9$ (where R^8 and R^9 are independently selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl, or R^8 and R^9 together with the nitrogen to which they are attached form a saturated heterocycloamino);

R^3 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aminoalkyl, -$C(O)R^7$ (where R^7 is as defined above), aryl, and heteroaryl;

R^4 is selected from the group consisting of hydrogen, alkyl, -$C(O)R^7$ (where R^7 is as defined above), aryl, and heteroaryl;

R^5 is 3-amino-2-hydroxypropylaminocarbonyl, N-(2-dimethylaminoethyl)-aminocarbonyl, N-(2-diethylaminoethyl)-N-methylaminocarbonyl, N-(3-dimethylaminopropyl)aminocarbonyl, N-(2-diethylaminoethyl)-aminocarbonyl, N-(3-ethylaminopropyl)aminocarbonyl, N-(3-ethylamino-2-hydroxypropyl)aminocarbonyl, N-(3-

diethylamino-propyl)aminocarbonyl, 3-amino-2-hydroxypropylaminocarbonyl, 3-dimethylamino-2-hydroxypropylaminocarbonyl, 3-diethylamino-2-hydroxypropylaminocarbonyl, N-(3-diethylamino-2-hydroxy-propyl)aminocarbonyl, N-(2-diethylaminoethyl)-aminocarbonyl or N-(ethylaminoethyl)aminocarbonyl; ~~is selected from the group consisting of hydrogen and $-COR^{10}$ where R^{10} is alkyl, alkoxy, hydroxy, aryl, aryloxy, heteroaryl, heterocyle, alkylamino, dialkylamino, or $-NR^{11}R^{12}$ where R^{11} is hydrogen or alkyl, and R^{12} is aminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, heteroaralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy group(s); or R^4 and R^5 together form $-(CH_2)_4-$ or $-(CH_2)_mCO(CH_2)_n-$ wherein n is 0 to 3, n is 0 to 3 provided that n+m is 3;~~

R^6 is:

(a) $-OR^{13}$ wherein R^{13} is alkyl, trifluoromethyl, carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, alkoxyalkyl, aryl, heteroaryl, heteroaralkyl, heterocyclyl, monosaccharides and heterocyclylalkyl wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two carbon atoms in said alkyl chain are optionally replaced by oxygen, $-NR^{14}-$ (where R^{14} is hydrogen or alkyl), –S-, or $-SO_2-$; or

(b) $-NR^{15}R^{16}$ where are R^{15} and R^{16} are independently selected from the group consisting of hydrogen, alkyl, carboxyalkyl, alkoxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, aryl, heteroaryl, heteroaralkyl, and heterocyclylalkyl; wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two carbon atoms in the alkyl chain are optionally replaced by oxygen, $-NR^{17}-$ (where R^{17} is hydrogen or alkyl), –S-, or $-SO_2-$; or

R^{15} and R^{16} together with the nitrogen atom to which they are attached form saturated or unsaturated heterocycloamino; or a pharmaceutically acceptable salt thereof.

2. (Original) A pharmaceutical composition, comprising a compound or salt of Claim 1 and a pharmaceutically acceptable carrier or excipient.

3. (Original) A method for the modulation of the catalytic activity of a protein kinase comprising contacting said protein kinase with a compound or salt of Claim 1.

4. (Original) The method of Claim 3 wherein said protein kinase is selected from the group consisting of a receptor tyrosine kinase, a non-receptor tyrosine kinase and a serine-threonine kinase.

5. (Original) A method for treating or preventing a protein kinase related disorder in a patient in need of such treatment comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound or salt of Claim 1 and, a pharmaceutically acceptable carrier or excipient to said patient.

6. (Original) The method of Claim 5 wherein said protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder and a serine-threonine kinase related disorder.

7. (Original) The method of Claim 6 wherein said protein kinase related disorder is selected from the group consisting of an EGFR related disorder, a PDGFR related disorder, an IGFR related disorder and a flk related disorder.

8. (Original) The method of Claim 7 wherein said protein kinase related disorder is a cancer selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.

9. (Original) The method of Claim 7 wherein said protein kinase related disorder is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, von Hippel-Lindau disease,

osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.

10. (New) The compound of Claim 1, wherein R^5 is N-(2-diethylaminoethyl)-aminocarbonyl.

11. (New) The compound of Claim 10, wherein R^3 and R^4 are lower alkyl having 1 to 4 carbon atoms.

12. (New) The compound of Claim 11, wherein R^3 and R^4 are methyl.

13. (New) The compound of Claim 12, wherein R^1 is hydrogen and R^2 is fluoro.

14. (New) The compound of Claim 13, wherein R^2 is a fluoro at the 5 position of the indolinone moeity.

15. (New) A pharmaceutical composition comprising the compound of Claim 14 and a pharmaceutically acceptable carrier or excipient.

16. (New) A compound of Formula (I):



(I)

wherein:

R^1 and R^2 are independently selected from the group consisting of hydrogen, halo, alkyl, alkylthio, nitro, trihalomethyl, hydroxy, hydroxyalkyl, alkoxy, cyano, aryl, heteroaryl, -$C(O)R^7$ (where R^7 is selected from the group consisting of alkyl, amino, hydroxy, alkoxy, aryl, heteroaryl, aryloxy, heteroaryloxy, heterocycle, and aminoalkylamino), -NR^8R^9, -$NR^8C(O)R^9$, -SO_2R^8, and –$S(O)_2NR^8R^9$ (where R^8 and R^9 are independently selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl, or R^8 and R^9 together with the nitrogen to which they are attached form a saturated heterocycloamino);

R^3 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aminoalkyl, -$C(O)R^7$ (where R^7 is as defined above), aryl, and heteroaryl;

R^4 is selected from the group consisting of hydrogen, alkyl, -$C(O)R^7$ (where R^7 is as defined above), aryl, and heteroaryl;

R^5 is 3-pyrrolidin-1-yl-propylaminocarbonyl, 3-morpholin-4-ylpropyl-aminocarbonyl, 2-pyrrolidin-1-ylethylaminocarbonyl, 2-morpholin-4-ylethylaminocarbonyl, 2-(4-methylpiperazin-1-yl)ethyl-aminocarbonyl, 2-(3,5-dimethylpiperazin-1-yl)ethylaminocarbonyl, 2-(3-ethoxycarbonylpiperazin-1-yl)ethylaminocarbonyl, 2-(3-oxopiperazin-1-yl)ethylaminocarbonyl, 2-(imidazolidin-1-yl-2-one)ethylaminocarbonyl, 2-(tetrahydropyrimidin-1-yl-2-one)-ethylaminocarbonyl, 2-(2-oxopyrrolidin-1-yl)ethylamino-carbonyl, 3-(4-methyl-piperazin-1-yl)propylaminocarbonyl, 3-(3-ethoxy-carbonylpiperazin-1-yl)propylaminocarbonyl, 3-(3-oxopiperazin-1-yl)propylaminocarbonyl, 3-(imidazolidin-1-yl-2-one)propyl-aminocarbonyl, 3-(tetrahydro-pyrimidin-1-yl-2-one)-propylaminocarbonyl, 3-(2-oxopyrrolidin-1-yl)propylamino-carbonyl, 2-(2-oxohomopiperidin-1-yl)ethylamino-carbonyl, 3-(2-oxohomopiperidin-1-yl)propylaminocarbonyl, 3-morpholin-2-hydroxypropylaminocarbonyl, 3-pyrrolidin-1-yl-2-hydroxypropyl-aminocarbonyl, 3-(4-methylpiperazin-1-yl)-2-hydroxypropylaminocarbonyl or 2-pyrrolidin-1-ylethylaminocarbonyl;

R^6 is:

(c) –OR^{13} wherein R^{13} is alkyl, trifluoromethyl, carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, alkoxyalkyl, aryl, heteroaryl, heteroaralkyl, heterocyclyl, monosaccharides and heterocyclylalkyl wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and

further wherein one or two carbon atoms in said alkyl chain are optionally replaced by oxygen, -NR^{14}- (where R^{14} is hydrogen or alkyl), –S-, or -SO_2-; or

(d) –$NR^{15}R^{16}$ where are R^{15} and R^{16} are independently selected from the group consisting of hydrogen, alkyl, carboxyalkyl, alkoxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, aryl, heteroaryl, heteroaralkyl, and heterocyclylalkyl; wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two carbon atoms in the alkyl chain are optionally replaced by oxygen, -NR^{17}- (where R^{17} is hydrogen or alkyl), –S-, or -SO_2-; or

R^{15} and R^{16} together with the nitrogen atom to which they are attached form saturated or unsaturated heterocycloamino; or a pharmaceutically acceptable salt thereof.

17. (New) The compound of Claim 16, wherein R^5 is 2-pyrrolidin-1-ylethylaminocarbonyl or 3-morpholin-2-hydroxypropylaminocarbonyl.

18. (New) The compound of Claim 17, wherein R^3 and R^4 are lower alkyl having 1 to 4 carbon atoms.

19. (New) The compound of Claim 18, wherein R^3 and R^4 are methyl.

20. (New) The compound of Claim 19, wherein R^1 is hydrogen and R^2 is halo.

21. (New) The compound of Claim 20, wherein R^2 is fluoro.

22. (New) The compound of Claim 21, wherein R^2 is a fluoro at the 5 position of the indolinone moeity and R^5 is 2-pyrrolidin-1-ylethylaminocarbonyl.

23. (New) A pharmaceutical composition comprising the compound of Claim 16.

24. (New) A pharmaceutical composition comprising the compound of Claim 17.

25. (New) A pharmaceutical composition comprising the compound of Claim 22.

26. (New) A compound of Formula (Ib):



(Ib)

wherein:

R^2 is selected from the group consisting of hydrogen, halo, alkyl, alkylthio, nitro, trihalomethyl, hydroxy, alkoxy, cyano, aryl, heteroaryl, $-C(O)R^7$ (where R^7 is selected from the group consisting of alkyl, amino, hydroxy, alkoxy, aryl, heteroaryl, aryloxy, and heteroaryloxy), $-NR^8R^9$, $-NR^8C(O)R^9$, $-SO_2R^8$, and $-S(O)_2NR^8R^9$ (where R^8 and R^9 are independently selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl);

R^3 is selected from the group consisting of hydrogen, alkyl, $-C(O)R^7$ where R^7 is selected from the group consisting of alkyl, amino, hydroxy, alkoxy, aryl, heteroaryl, aryloxy, and heteroaryloxy, aryl, and heteroaryl;

R^4 is selected from the group consisting of hydrogen, alkyl and $-C(O)R^7$ where R^7 is as defined above;

R^5 is $-COR^{10}$ where R^{10} is alkyl, alkoxy, hydroxy, aryl, aryloxy, heteroaryl, heterocyle, alkylamino, dialkylamino, or
$-NR^{11}R^{12}$ where R^{11} is hydrogen or alkyl, and R^{12} is aminoalkyl, dialkylaminoalkyl, heteroarylalkyl, hydroxyalkyl, heteroaralkyl, or heterocyclylalkyl wherein the alkyl chain in alkylamino, heteroaralkyl or heterocylylalkyl is optionally substituted with one or two hydroxy group(s);

R^6 is:

(i) $-OR^{13}$ wherein R^{13} is alkyl, trifluoromethyl, carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, alkoxyalkyl, aryl, heteroaryl, heteroaralkyl, heterocyclyl, monosaccharides and heterocyclylalkyl wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, heteroaralkyl, hydroxyalkyl or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two carbon atoms in said alkyl chain are optionally replaced by oxygen, $-NR^{14}-$ (where R^{14} is hydrogen or alkyl), –S-, or $-SO_2-$; or

(ii) $-NR^{15}R^{16}$ where are R^{15} and R^{16} are independently selected from the group consisting of hydrogen, alkyl, carboxyalkyl, alkoxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, aryl, heteroaryl, heteroaralkyl, and heterocyclylalkyl; wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, heteroaralkyl or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two carbon atoms in the alkyl chain are optionally replaced by oxygen, $-NR^{17}-$ (where R^{17} is hydrogen or alkyl), –S-, or $-SO_2-$; or

R^{15} and R^{16} together with the nitrogen atom to which they are attached form saturated or unsaturated heterocycloamino; or

a pharmaceutically acceptable salt thereof.

27. (New) The compound of Claim 26, wherein R^5 is N-(2-diethylaminoethyl)-aminocarbonyl, 2-pyrrolidin-1-ylethylaminocarbonyl, or 3-morpholin-2-hydroxypropyl-aminocarbonyl.

28. (New) The compound of Claim 27, wherein R^2 is halo.

29. (New) The compound of Claim 28, wherein R^2 is fluoro.

30. (New) The compound of Claim 29, wherein R^3 and R^4 are hydrogen, methyl, ethyl, propyl, or butyl.

31. (New) The compound of Claim 29, wherein R^3 and R^4 are methyl.

32. (New) A pharmaceutical composition comprising the compound of Claim 26 and a pharmaceutically acceptable carrier or excipient.

33. (New) A pharmaceutical composition comprising the compound of Claim 27 and a pharmaceutically acceptable carrier or excipient.

34. (New) A pharmaceutical composition comprising the compound of Claim 31 and a pharmaceutically acceptable carrier or excipient.